Current Advances in Immune Checkpoint Therapy
Although immune checkpoint inhibitors (ICIs) have shown survival benefits for patients with metastatic cancers, some challenges have been under intense study in recent years. The most critical challenges include the side effects and the emergence of resistance. Potential opportunities exist to devel...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2023
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/84040 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Although immune checkpoint inhibitors (ICIs) have shown survival benefits for patients with metastatic cancers, some challenges have been under intense study in recent years. The most critical challenges include the side effects and the emergence of resistance. Potential opportunities exist to develop personalized immune checkpoint inhibitor therapy based on biomarker discovery. Combinational therapy involving immune checkpoint inhibitors and other forms of anticancer therapies has varied success. This chapter reviews drugs currently undergoing Phase III clinical trials and others that are FDA-approved. We take a critical look at the combinational strategies and address the ever-present challenge of resistance. Moreover, we review and evaluate the discovery of biomarkers and assess prospects for personalized immune checkpoint therapy. |
|---|---|
| ISBN: | 978-1-80356-590-3 |
| DOI: | 10.5772/intechopen.107315 |